The great DNA letdown by Jennifer Lai @FortuneMagazine April 8, 2010, 2:51 PM EDT E-mail Tweet Facebook Google Plus Linkedin Share icons A decade ago, scientists promised a revolution in drug development as they mapped the human genome. What went wrong? By David Ewing Duncan, contributor This is science as a biopic: the stars are four regular guys named A, T, C, and G. Like the mop-top Beatles who came from Liverpool nearly 50 years ago, this Fab Four are the superstars of our era, which has been dubbed the Age of Genomics. Since scientists announced the sequencing of nearly every A, T, C, and G in humans a decade ago, their influence has permeated movies, comics, books, newscasts, universities, lecture halls, and the blogosphere. Governments and life science companies large and small have lavished hundreds of billions of dollars on genetic research and development. Thousands of scientists and hundreds of companies — including many in the Fortune 500 — still labor to tease out the secrets of these often elusive sequences of genetic code tucked inside of our cells, and how they impact disease, behavior, and life itself. Fans of the Human Genome Project have compared it to the Apollo Program, and called it “the book of life.” Not since Einstein’s E = mc² had science been so sexy and exciting, with just a tinge of danger. But 10 years later, the accomplishments, in terms of human health, have failed to live up to the hype, according to top scientists writing in Nature. “Some major advances have indeed been made,” opines the lead editorial in Nature, “powerful new drugs have been developed for some cancers; genetic tests can predict whether people with breast cancer need chemotherapy; the major risk factors for macular degeneration have been identified; and drug response can be predicted accurately for more than a dozen drugs. But it is fair to say that the Human Genome Project has not yet directly affected the health care of most individuals.” Nor has it produced the raft of products (and profits) expected in 2000 when President Bill Clinton stood in the East Room of the White House with leading scientists to announce the near completion of the Human Genome Project. “With this profound new knowledge, humankind is on the verge of gaining immense, new power to heal,” he declared. Biotech companies like Celera Group CRA , Millennium Pharmaceuticals, Human Genome Sciences HGSI , and deCode Genetics raised billions of dollars in the years just before and after the White House ceremony. They promised not only a raft of new drugs based on a deeper understanding of genetics but also billions of dollars in revenues. Big Pharma companies invested heavily in these companies and in their own genomics programs. The genome allure came in part from the simplicity and elegance of the code. Unlike most of biology, which is complicated, sloppy, and quite literally wet and slimy, DNA was clean and digital. It reminded engineers and IT people of computer code, and the analogy still used was born that DNA was indeed the computer code of life. Most biologists were less giddy about DNA. From the start, they suspected that the biology of humans at the molecular level would be more complex, and that the idea that a “gene” for common diseases like diabetes and heart disease could be identified and a drug made to modulate this “target” was too simplistic. And yet this model became a primary thrust of most pharma companies — and for many, it still is. The biologists were right For most of us, our DNA is part of a complex dynamic that includes the impact of the environment — food, UV rays from the sun, toxins — and the interplay of everything from microbes that dwell inside our bodies to a host of structures in our cells that interact with and impact DNA. It’s possible that the obsession with DNA actually hindered or slowed the study and development of other approaches to understanding and treating disease. If nothing else, it diverted resources to companies and efforts that are now almost all gone — bankrupt, sold, or redirected away from pure genomics. This distraction may explain why the number of novel drugs approved by the Food and Drug Administration dropped from a peak of 53 in 1996 to 25 last year. (The good news is that this is up from only 11 novel drugs approved in 2005.) The genetics craze also created the impression that dozens of DNA markers associated with common diseases can be used to predict one’s risk of acquiring that disease. In some cases this is true — for instance, for some cancers and for macular degeneration, a disease that causes blindness. Most of the genetic tests offered by online companies, such as 23andme and deCodeme, however, have not been scientifically validated. Even if they have, they usually reveal only a slightly elevated risk factor for disease. This may explain why only 35,000 customers have signed up for 23andme — a company that has received lavish attention since launching in 2007. In 2008, Time magazine named 23andme, and personalized genomics, the innovation of the year. All is not lost, says human genome project leader Francis Collins, now the Director of the National Institutes of Health. “The promise of a revolution in human health remains quite real,” he writes in a Nature commentary. “Those who somehow expected dramatic results overnight may be disappointed, but should remember that genomics obeys the First Law of Technology: we invariably overestimate the short-term impacts of new technologies and underestimate their longer-term effects.” This is why the editors at Nature intriguingly have suggested that perhaps another coordinated Big Science effort like the Human Genome Project is needed to bridge what is fast becoming a huge gap between the valuable research being produced in the wake of the Human Genome Project and its application in health and medicine. “The ten years since have brought astounding technological and intellectual advances,” write the Nature editors. “But ten years from now, when the story of the genome’s first two decades is being told, it should include equally astounding applications to human health.” This leaves us fans eagerly awaiting the next chapter in the biopic of the Fab Four — the one where they venture out and embrace the rest of the world, to make the music of cures — that will truly be for the ages.